Prader-Willi-like syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
Mar 2026CARBIDOPA AND LEVODOPA: New indication approved
FDAcompleted
Mar 2026CREXONT: New indication approved
FDAcompleted
Mar 2026DUOPA: New indication approved
FDAcompleted
Mar 2026SINEMET: New indication approved
FDAcompleted
Mar 2026WEGOVY: New indication approved
FDAcompleted
Mar 2026WEGOVY: New indication approved
FDAcompleted
Feb 2026WEGOVY: New indication approved
FDAcompleted
Feb 2026WEGOVY: New indication approved
FDAcompleted
Jan 2026WEGOVY: New indication approved
FDAcompleted
Jan 2026WEGOVY: New indication approved
FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

DUOPA

AbbVie Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Prader-Willi-like syndrome.
Search all trials →
Search clinical trials for Prader-Willi-like syndrome

Recent News & Research

1 article
BREAKINGFDAMar 19, 2026

FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.

Read ↗

Browse all Prader-Willi-like syndrome news →

Specialist Network

Top 6 by expertise

View all Prader-Willi-like syndrome specialists →

Quick Actions